drugset / Trial / NCT01649388
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
NaSingle-groupOpen-labelTreatment
Summary
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
Timeline
- Start
- 2012-10-15
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
Outcome
Outcome not reported
Stopped: “study terminated by sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FCR001 | Cell therapy | — | — |
Indications
No indication recorded.